title: Study of the therapeutic effect of 188Re labeled folate targeting albumin nanoparticle coupled with cis-diamminedichloroplatinum cisplatin on human ovarian cancer.
abstract: This paper aimed to investigate the treatment efficiency of 188Re labeled folate targeting albumin nanoparticles with cis-Diamminedichloroplatinum Cisplatin (188Re-folate-CDDP/HAS MNP) on human ovarian cancer. SKOV3 cells or tumor-bearing mice were divided into different groups and treated as follow: (A) negative control; (B) chemotherapy; (C) radiotherapy; (D) hyperthermia; (E) chemotherapy and radiotherapy; (F) chemotherapy and hyperthermia; (G) radiotherapy and hyperthermia; (H) chemotherapy, radiotherapy and hyperthermia. Treatment of B to H inhibited proliferation of SKOV3 cells, with the greatest inhibition being observed in group H (P<0.05). Obvious apoptotic hypodiploid peak appeared beside G1 phase in groups of B to H. The apoptotic rates of SKOV3 cells in groups of A to H were 0.08%, 7.56%, 8.64%, 17.14%, 21.64%, 23.77%, 33.94% and 57.16%, respectively. Our findings in vivo study showed that the mass of tumor in each group of B to H was significantly lower than that in the negative control (p <0.05). In addition, compared with each group of B to G, group H showed highest inhibition of tumor growth (p<0.05). In conclusion, the combination of magnetic induced hyperthermia, chemotherapy and targeted radionuclide of radiation exposure can effectively inhibit the growth of ovarian cancer, which indicates a potential applications in ovarian cancer treatment.
authors.affiliation: School of Medical Science, Southeast University, No. 87, Dingjiaqiao Road, Nanjing 210009, Jiangsu Province, China.
authors.forename: Qiusha
authors.initials: Q
authors.lastname: Tang
authors.forename: Daozhen
authors.initials: D
authors.lastname: Chen
mesh_terms: D000418:Albumins / Q000737:chemistry*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin / Q000008:administration & dosage* / Q000494:pharmacology; D003131:Combined Modality Therapy; D004337:Drug Carriers / Q000737:chemistry; D005260:Female; D005492:Folic Acid / Q000737:chemistry*; D006801:Humans; D006979:Hyperthermia, Induced; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011868:Radioisotopes / Q000032:analysis; D012211:Rhenium / Q000032:analysis
chemical_list: D000418:Albumins; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008024:Ligands; D011868:Radioisotopes; D012211:Rhenium; D005492:Folic Acid; D002945:Cisplatin
keywords: 188Reovarian cancer; Cisplatin; albumin magnetic nanoparticles; combinated therapy; folic acid